- |||||||||| CoronaVac / Sinovac, Bio Farma Indonesia, Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Review, Journal: Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines. (Pubmed Central) - Feb 22, 2022 Among them are BioNTech and Moderna vaccines (mRNA based); ChAdOx1, Gam-COVID-Vac, Janssen vaccines (vector-based); CoronaVac, COVAXIN (virus inactivated); and EpiVacCorona vaccine (viral peptide)...However, no definitive relationship could be established between vaccination administration and the occurrence of these complications. None of the COVID-19 vaccines approved to date have been found to be effective against all of the SARS-CoV-2 variants.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients. (Pubmed Central) - Feb 19, 2022 The link between the COVID-19 vaccine and GBS is not well understood. Given the prevalence of GBS over the population, this association may be coincidental; therefore, more studies are needed to investigate a causal relationship.
- |||||||||| CoronaVac / Sinovac, Bio Farma Indonesia, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Breakthrough COVID Infections: Prevalence of Critical COVID-19 Disease Among Post-Vaccinated Patients in a Tertiary Hospital in the Philippines (Area J, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_2607; The Philippines is among the countries with the most number of approved COVID-19 vaccines...The most common vaccine associated with breakthrough critical COVID-19 infection was Coronavac. This poses a challenge to public health policy on how best to implement a vaccination program that will mitigate risk for the development of critical covid infection post-vaccination.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Severe Persistent Eczema in a Recipient of the Gam-COVID-Vac vaccine. (Pubmed Central) - Feb 17, 2022 Moreover, a severe allergic reaction to a COVID-2019 vaccine may indicate the vaccine is ineffective in the recipient. Vaccination against COVID-19 may be accompanied by rare complications.Eczematous lesions can be a side effect of the Sputnik V vaccine.A severe allergic reaction to a COVID-19 vaccine may result in decreased vaccine effectiveness in the recipient.
- |||||||||| Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
Review, Journal: Review of COVID-19 viral vector-based vaccines and COVID-19 variants. (Pubmed Central) - Feb 12, 2022 The technology has been used to make Ebola vaccines and now COVID-19 vaccines...Current adenovirus vector-based vaccines being administered against SARS-CoV-2 infection are JNJ-78435735 by Johnson and Johnson (Janssen) along with Beth Israel Deaconess Medical Center, AZD1222 by Oxford-AstraZeneca, Sputnik V and Sputnik Light by Gamaleya Research Institute of Epidemiology and Microbiology, and Convidecia vaccine by CanSino Biologics...Efficacy against COVID-19 variants has been found in all but the Convidecia vaccine so far. Heterologous prime-boost COVID-19 vaccination regimen may be the new face and more efficient immunization approach for enhanced immunity against COVID-19.
- |||||||||| Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Review, Journal, Adverse events: A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. (Pubmed Central) - Feb 8, 2022 Apart from the common adverse effects such as fever, fatigue, headache, and pain in the injection site, Bell's palsy with BNT162b2, myocarditis and pericarditis with mRNA-1273, and thrombosis with ChAdOx1 nCoV-19 have been reported though seemed not alarming. Furthermore, global production and distribution of vaccines should be ensured in an equal and justifiable way that the immunity and protection against the virus would be optimum and persistent.
- |||||||||| BBIBP-CorV / Wuhan Institute of Virology, Sinopharm, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
SARS-CoV-2-specific T Cell Immunity after Vaccination with Sputnik V and BBIBP-CorV () - Feb 4, 2022 - Abstract #AAAAI2022AAAAI_1970; SARS-CoV-2-specific T cell responses developed in 26.6% and 31.6% of patients after Sputnik V and BBIBP-CorV vaccination, respectively. BBIBP-CorV vaccination also stimulated T cells specific to N and M antigens of SARS-CoV-2.
- |||||||||| Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Clinical, Review, Journal: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. (Pubmed Central) - Feb 1, 2022 Questions remain regarding a booster dose and waning immunity, the duration of immunity, and heterologous vaccination. The benefits of COVID-19 vaccination outweigh the risks, despite rare serious adverse effects.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia. (Pubmed Central) - Feb 1, 2022 In a survey of 1,080 residents of Arkhangelsk 40-75 years of age, 65% were seropositive for IgG. Fifteen percent of participants had been vaccinated; of those, 97% were seropositive.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort. (Pubmed Central) - Jan 27, 2022 Herein, we show for the first time, evidence of infectious SARS-CoV-2 shedding from Sputnik-V fully vaccinated individuals, by the isolation of viable virus from the nasopharyngeal swab of one participant of our study, 139 days after receiving the second dose. Thereby, we provide evidence indicating that the vaccine might avoid severe forms of COVID-19 but does not prevent infection nor prevents transmission from a fully vaccinated individual.
- |||||||||| Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Clinical, Journal: Efficacy of Covid-19 vaccines: several modes of expression should be presented in scientific publications. (Pubmed Central) - Jan 18, 2022 Using main publications, absolute risks (AR), AR reduction (ARR), number needed to treat (NNT) were calculated for five COVID-19 vaccines (tozinameran Comirnaty®, Moderna, Vaxzevria®, Janssen, and Sputnik V vaccines)...The order of the different vaccines was not the same according to the chosen efficacy parameters. This is a further example of the need to express results of clinical trials, using not only RR, but also AR, ARR and NNT in order to clearly present the clinical interest of drugs.
- |||||||||| Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Enrollment closed, Trial completion date, Trial primary completion date: Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention (clinicaltrials.gov) - Jan 11, 2022 P2, N=100, Active, not recruiting, This work necessitates the need for further clinical assessments with larger sample sizes. Not yet recruiting --> Active, not recruiting | Trial completion date: Sep 2021 --> Mar 2022 | Trial primary completion date: Apr 2021 --> Nov 2021
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Why not Sputnik V (Twitter) - Dec 30, 2021
|